Gender Disparities in Head and Neck Cancer Treatment?


A California study showed women are significantly undertreated for head and neck cancer, with several factors possibly accounting for the disparity.

Women are being significantly undertreated for head and neck cancer, according to the results of a study (abstract LBA6002) presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 1–5. An analysis of a cancer registry in California has found that women with head and neck cancer were less likely to receive intensive chemotherapy and radiation, compared with men.

“We weren’t looking for gender differences, so the results were really surprising,” said senior study author Jed A. Katzel, MD, a medical oncologist at Kaiser Permanente in Santa Clara, California. 

The researchers evaluated health outcomes for 223 female and 661 male patients with stages II–IVB head and neck cancer treated at Kaiser Permanente Northern California. The odds of receiving intensive cancer treatment were estimated using logistic regression models. The researchers also adjusted for factors such as age, gender, tumor stage, Charlson Comorbidity Index, and history of smoking and alcohol use.

The team used a mathematical tool, the generalized competing event (GCE) model, to compare the risk of dying from cancer to the risk of dying from other causes. The GCE model controls for differences in age, gender, tumor site, and Charlson score. The researchers found that the odds of receiving intensive chemotherapy were 35% for women vs 46% for men, and the odds of receiving radiation were 60% for women and 70% for men.

At a median follow-up of 2.9 years, 271 patients had died of cancer and 93 died from other causes. While both men and women were more likely to die of cancer than of other causes, the ratio of cancer deaths vs noncancer deaths was 1.92 times higher for women than for men.

While further analysis is ongoing, one of the factors that must be considered is that the researchers did not control for differences in tumor type with respect to HPV status. HPV-related head and neck tumors are more responsive to treatment, and patients with such cancers generally have a better prognosis. HPV-related head and neck cancer is more common in men than in women. In the authors’ prior analysis of patients in Northern California, they found that only about 22.6% of HPV-related cancers occurred in women, compared with 77.4% in men.

“Besides undertreatment, there are a number of factors that could contribute to the differences in outcomes between women and men with head and neck cancer, and it’s clear we need further investigation,” said Dr. Katzel.

Commenting on the study, ASCO Expert Joshua A. Jones, MD, from Perelman School of Medicine at the University of Pennsylvania, Philadelphia, said it is unknown if what is occurring in California reflects what is happening elsewhere in the United States. “Though these findings are specific to California, the disparities we see are startling and worth considering in treatment discussions in everyday practice,” Dr. Jones said. “We don’t know why women are getting less treatment and having worse outcomes, and we need to find out.”





Recent Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Related Content